.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 4,584,187

« Back to Dashboard

Claims for Patent: 4,584,187

Title: Imaging agent and method of use
Abstract:A new radiopharmaceutical composition for use in nuclear medicine comprises a radioiodinated meta-iodobenzylguanidine. The composition is used as an imaging agent for the heart, adrenal medulla, and tumors of the adrenal medulla and can be used for treatment of tumors of the adrenal medulla.
Inventor(s): Wieland; Donald M. (Ann Arbor, MI), Brown; Lawrence E. (Ypsilanti, MI), Beierwaltes; William H. (Ann Arbor, MI), Wu; Jiann-long (Walnut Creek, CA)
Assignee:
Application Number:06/250,059
Patent Claims: 1. A radioiodinated compound I-metaiodobenzylguanidine wherein I is an isotope selected from I.sup.123 and I.sup.131.

2. The compound of claim 1 wherein I is the 123 isotope.

3. The compound of claim 1 wherein I is the 131 isotope.

4. A radiopharmeceutical comprising radioiodinated I-meta-iodobenzylguanidine and a carrier.

5. The composition of claim 4 wherein said carrier is a physiological buffered saline solution.

6. The composition of claim 4 comprising .sup.123 I-meta-iodobenzylguanidine.

7. The composition of claim 4 comprising .sup.131 I-meta-iodobenzylguanidine.

8. The composition of claim 6 wherein said .sup.123 I-meta-iodobenzylguanidine is present in an effective amount of from about 1.0 to about 3.0 mCi.

9. The composition of claim 7 wherein said .sup.131 I-meta-iodobenzylguanidine is present in an effective amount of from about 0.2 to about 1.0 mCi.

10. The composition of claim 7 wherein said .sup.131 I-meta-iodobenzylguanidine is present in an effective amount of from about 100 to about 200 mCi.

11. A method of radio-imaging a human organ comprising the steps of:

(a) systemically applying a pharmaceutical composition comprising radioiodinated meta-iodobenzylguanidine to a human;

(b) detecting gamma radiation emitted by said composition and forming an image therefrom.

12. The method of claim 11 wherein said pharmaceutical composition comprises a physiological buffered saline carrier.

13. The method of claim 11 wherein said composition comprises .sup.123 I-meta-iodobenzylguanidine.

14. The method of claim 13 wherein said .sup.123 I-meta-iodobenzylguanidine is present in an effective amount of from about 1.0 to about 3.0 mCi.

15. The method of claim 11 wherein said composition comprises .sup.131 I-meta-iodobenzylguanidine.

16. The method of claim 15 wherein said .sup.131 I-meta-iodobenzylguanidine is present in an effective amount of from about 0.2 to about 1.0 mCi.

17. The method of claim 11 wherein said human organ is selected from the group consisting of the heart, adrenal medulla, and tumors of the adrenal medulla.

18. A method of therapeutically treating a tumor, comprising systemically applying a pharmaceutical composition comprising radioiodinated meta-iodobenzylguanidine to a human.

19. The method of claim 18 wherein said composition comprises, in addition, a physiological buffered saline carrier.

20. The method of claim 18 wherein said composition comprises .sup.131 I-meta-iodobenzylguanidine.

21. The method of claim 20 wherein said .sup.131 I-meta-iodobenzylguanidine is present in an effective amount of from about 100 to about 250 mCi.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc